Treatment of gluten intolerance and related conditions

Patent metadata

Field	Value
Publication number	US-11725198-B2
Application number	US-202117209879-A
Country	US
Kind code	B2
Filing date	Mar 23, 2021
Priority date	Nov 21, 2012
Publication date	Aug 15, 2023
Grant date	Aug 15, 2023

Abstract

Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori . Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.

First claim

What is claimed is:

1. A method for treating or attenuating gluten intolerance in a patient in need thereof, comprising administering to said patient an effective amount of nepenthesin, wherein said nepenthesin comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, wherein the nepenthesin has protease activity.

2. The method of claim 1 , wherein the nepenthesin is without a plant signal sequence.

3. The method of claim 1 , wherein the protease activity is at a pH where the protease is active against gluten.

4. The method of claim 1 , wherein the protease activity is aspartic protease activity.

5. The method of claim 1 , wherein the effective amount of said nepenthesin is sufficient to degrade gluten to treat or attenuate gluten intolerance.

6. The method of claim 1 , wherein said nepenthesin is administered to the patient prior to ingestion of a food comprising gluten or suspected of comprising gluten.

7. The method of claim 1 , wherein said nepenthesin is administered to the patient with ingestion of a food comprising gluten or suspected of comprising gluten.

8. The method of claim 1 , wherein said nepenthesin is administered to the patient after ingestion of a food comprising gluten or suspected of comprising gluten.

9. The method of claim 1 , wherein said nepenthesin is mixed with food comprising gluten or suspected of comprising gluten prior to consumption of the food by the patient.

10. The method of claim 9 , wherein the food prior to consumption is at a pH wherein said nepenthesin is inactive.

11. The method of claim 10 , wherein the pH is 5 or above.

12. The method of claim 9 , wherein the mixture of nepenthesin and food comprising gluten or suspected of comprising gluten is not heated to conditions in which said nepenthesin is inactivated prior to consumption.

Assignees

• Codexis Inc

Inventors

• Schriemer David C
• Man Petr
• Mrazek Hynek
• Rey Martial

Classifications

• C12N9/63 Primary

  derived from plants · CPC title

• A23L29/06 Primary

  Enzymes · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title

• A23L33/105

  Plant extracts, their artificial duplicates or their derivatives · CPC title

• A61K38/488

  Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E · CPC title